Conciseness

The body is dense with domain-specific value (tool names per phase, signal thresholds like "PRR >= 2.0 AND lower CI > 1.0 AND N >= 3", edge cases) and mostly assumes Claude's competence. Minor trimmable padding: the 10-phase ASCII workflow diagram largely duplicates the Phase Summaries, and the Naranjo algorithm walkthrough re-explains a framework Claude largely knows. Not anchor 5 ('every token earns its place') because of that duplication, and clearly not anchor 3's 'unnecessary explanation' territory.

Actionability

Concrete, executable guidance throughout: exact tool names per phase (e.g. "FAERS_calculate_disproportionality", "OpenTargets_get_drug_chembId_by_generic_name"), explicit signal criteria and strength cutoffs, and a point-weighted scoring rubric ("FAERS signal strength (0-35), serious AEs (0-30), FDA label warnings (0-25), literature evidence (0-10)"). Not anchor 5 because no inline executable examples or tool-call snippets appear — examples and output templates are entirely deferred to reference files.

Workflow Clarity

A clear 10-phase sequence with per-phase outputs, explicit signal criteria acting as checkpoints, error-handling guidance ("{error: {code: \"NOT_FOUND\"}} is normal when a section does not exist"), an Edge Cases section with fallbacks ("No FAERS reports: Skip Phases 1-2"), and a completeness checklist in Phase 9. Not anchor 5 because validation between phases is implicit (criteria stated but no explicit verify-then-branch loop like the validate/fix/re-validate example).

Progressive Disclosure

References are clearly signaled and one level deep ("Reference files (in this directory): PHASE_DETAILS.md, REPORT_TEMPLATE.md, TOOL_REFERENCE.md, QUICK_START.md" plus inline "See PHASE_DETAILS.md for scoring rubric"), and critical details are correctly split out. However, none of the four referenced files exist in the bundle — no references/, scripts/, or assets/ directories are present — so the disclosure chain is broken and the promised detail (signal classification table, scoring rubric, report template) is actually inaccessible. This lands at anchor 3 ('structure present but not fully delivering') rather than 4.

Specificity

Multiple specific concrete actions are named: "Detect and analyze adverse drug event signals using FDA FAERS reports, drug labels, and disproportionality statistics (PRR, ROR, IC)" and "Generates quantitative safety signal scores (0-100) with evidence grading". Specific data sources, statistics, and output format are all explicit; not the vague anchor below ("Processes PDF files"-level generality) because capabilities are enumerated with concrete parameters.

Completeness

Explicitly answers both questions: a concrete 'what' (detect/analyze AE signals with named statistics; generate 0-100 scores with evidence grading) and an explicit 'when' clause ("Use for post-market surveillance, pharmacovigilance, drug safety assessment, regulatory submissions, and detecting rare AE signals not visible in clinical trials") with concrete trigger phrases, matching the top anchor.

Trigger Term Quality

Natural user-facing phrases present: "post-market surveillance", "pharmacovigilance", "drug safety assessment", "regulatory submissions", "FAERS", "adverse drug event signals". Falls between anchors 4 and 5: good coverage but misses common synonyms a user would say, e.g. "side effects", "adverse reactions", "drug safety profile".

Distinctiveness Conflict Risk

The FAERS/disproportionality/safety-score framing carves a clear niche with minimal conflict risk against generic skills. However, it does not self-distinguish from a sibling pharmacovigilance skill — the differentiation (signal quantification vs. general pharmacovigilance) lives only in the body, so minor overlap risk remains.